Avadel Pharma (AVDL) Tops Q3 EPS by 5c

Avadel Pharma (NASDAQ: AVDL) reported Q3 EPS of ($0.03), $0.05 better than the analyst estimate of ($0.08). Revenue for the quarter came in at $50.03 million versus the consensus estimate of $48.44 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley on Exelixis (EXEL): today's update 'mixed-to-negative at the margin'
• Apple investigating exposure to Tata Electronics data breach, full analysis underway - Reuters